Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
نویسندگان
چکیده
Pancreatic neuroendocrine tumors (PanNETs) are frequently diagnosed at unresectable stage and remain a medical challenge. Everolimus (RAD001, Afinitor(®), Novartis, Basel, Switzerland), an orally administered inhibitor of mammalian target of rapamycin (mTOR), was recently approved by the Food and Drug Administration to treat patients with advanced PanNETs. This review will examine the mechanism of action of everolimus, the function of mTOR and its inhibition, PanNETs and the mTOR pathway, and clinical trials of everolimus in PanNETs. Future investigations will focus on everolimus combination therapy to treat PanNETs and the discovery of predictive biomarkers for response to everolimus.
منابع مشابه
Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone secretion may require specific medical interventions to control those symptoms prior to antitumor intervention. In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be required for diagnosis. Other patients may present with more advanc...
متن کاملEverolimus and mTOR inhibition in pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or moderately differentiated pancreatic neuroendocrine tumors have not significantly impeded tumor progression nor improved survival. However, recent mapping of intracellular signaling pathways promoting tumor proliferation...
متن کاملMINI REVIEW A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors
Gastroenteropancreatic neuroendocrine tumors are rare neoplasms; past decades have seen limited research channeled into this area. Recently, 2 placebocontrolled phase III trials using 2 drugs—everolimus and sunitinib—with distinct molecular rationales achieved their principal objective of increasing survival in patients with advanced pancreatic neuroendocrine tumors (PNET). Nonetheless, several...
متن کاملA case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor
BACKGROUND Although pancreatic neuroendocrine tumors generally have a far better prognosis relative to pancreatic cancer, the varied manifestations lead to treatment-related challenges. Everolimus therapy is generally recommended for patients with advanced pancreatic neuroendocrine tumors; however, its efficacy in a neoadjuvant setting remains unclear. Here we present a case of a giant pancreat...
متن کاملImpact of Prior Chemothe rapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial
Objective: The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior chemotherapy use in the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3). Methods: Patients with advanced, progressive, lowor intermediate-grade pNETwere prospectively stratified by prior chemotherapy use and World Health Organizat...
متن کامل